Literature DB >> 21123287

Changes in the classification and management of skin and soft tissue infections.

Roland Koerner1, Alan P Johnson.   

Abstract

Although skin and soft tissue infections (SSTIs) are extremely common in both primary and secondary care, there is a lack of validated evidence-based schemes for the classification of clinical presentation or severity, and there are few data available on treatment outcomes. The commonly used 'Eron classification' is based on the consensus views of an expert panel, while the Clinical Resource Efficiency Support Team (CREST) 'Guidelines on the Management of Cellulitis in Adults' have not been validated in clinical trials. In the current issue of JAC, investigators at Ninewells Hospital in Dundee, Scotland, report a retrospective study of patients with SSTIs who were treated with antibiotics. The patients were stratified into four classes of clinical severity, based on the presence or absence of sepsis and co-morbidity, and their standardized early warning score. The empirical treatment received by patients in each class was compared with the recommendations of the CREST guidelines. The findings do not make comfortable reading. Overall, 43% of patients (and 65% at the mildest end of the clinical spectrum) were overtreated, while mortality (at 30 days) and inadequate antimicrobial therapy increased with severity class. Strikingly, 35 different empirical antimicrobial prescribing regimens were noted. These findings, which are likely to reflect the situation in many hospitals, show that SSTIs remain a significant cause of mortality and that empirical therapy is bordering on the haphazard, with significant under treatment of severely ill patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123287     DOI: 10.1093/jac/dkq443

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Endogenous endophthalmitis secondary to erysipelas.

Authors:  José F Costa; João Pedro Marques; Marco Marques; Maria João Quadrado
Journal:  BMJ Case Rep       Date:  2015-06-29

2.  Application of orange essential oil as an antistaphylococcal agent in a dressing model.

Authors:  Arunachalam Muthaiyan; Debabrata Biswas; Philip G Crandall; Brian J Wilkinson; Steven C Ricke
Journal:  BMC Complement Altern Med       Date:  2012-08-16       Impact factor: 3.659

3.  Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection.

Authors:  David A Talan; Bisan A Salhi; Gregory J Moran; William R Mower; Yu-Hsiang Hsieh; Anusha Krishnadasan; Richard E Rothman
Journal:  West J Emerg Med       Date:  2014-12-10

4.  Deviating from IDSA treatment guidelines for non-purulent skin infections increases the risk of treatment failure in emergency department patients.

Authors:  J P Haran; E Wilsterman; T Zeoli; M Goulding; E McLendon; M A Clark
Journal:  Epidemiol Infect       Date:  2018-12-05       Impact factor: 2.451

Review 5.  Accuracy of CREST Guideline in Management of Cellulitis in Emergency Department; a Systematic Review and Meta-analysis.

Authors:  Hossein Akhavan; Seyed Reza Habibzadeh; Fatemeh Maleki; Mahdi Foroughian; Sayyed Reza Ahmadi; Reza Akhavan; Bita Abbasi; Behzad Shahi; Navid Kalani; Naser Hatami; Amir Mangouri; Sheida Jamalnia
Journal:  Arch Acad Emerg Med       Date:  2021-11-03

6.  Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center.

Authors:  Kimberly C Claeys; Abdalhamid M Lagnf; Trishna B Patel; Manu G Jacob; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2015-06-09

7.  Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Authors:  Daniel H Deck; Jennifer M Jordan; Thomas L Holland; Weihong Fan; Matthew A Wikler; Katherine A Sulham; G Ralph Corey
Journal:  Infect Dis Ther       Date:  2016-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.